Clinical Trials | March 03, 2026
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
This study evaluated a difficult-to-treat Crohn's disease patient population
This study evaluated a difficult-to-treat Crohn's disease patient population
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Improvements were also seen in complete response rates, duration of response, and time to next treatment
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Subscribe To Our Newsletter & Stay Updated
